ProPhase pares costs, preps relaunches
This article was originally published in The Tan Sheet
Executive Summary
The OTC firm, formerly known as Quigley, discontinues a candy product line and shutters a contract manufacturing facility, reducing first-quarter operating costs and expenses 51 percent to $2.2 million. ProPhase Labs' net sales in the January-March period also dropped 50.4 percent to $2 million, but its year-over-year net loss was halved to $1.1 million. Sales took a hit as retailer orders of cold and flu products, such as ProPhase's Cold-EEZE zinc lozenges, were front-loaded in fourth quarter 2009, according to CEO Ted Karkus. He added May 17 ProPhase is entering "a wonderful new phase," with redesigned packaging, a new mint frost Cold-EEZE flavor and the planned reintroduction of a Kids-EEZE non-liquid product line (1"The Tan Sheet" May 10, 2010, In Brief)
|
The OTC firm, formerly known as Quigley, discontinues a candy product line and shutters a contract manufacturing facility, reducing first-quarter operating costs and expenses 51 percent to $2.2 million. ProPhase Labs' net sales in the January-March period also dropped 50.4 percent to $2 million, but its year-over-year net loss was halved to $1.1 million. Sales took a hit as retailer orders of cold and flu products, such as ProPhase's Cold-EEZE zinc lozenges, were front-loaded in fourth quarter 2009, according to CEO Ted Karkus. He added May 17 ProPhase is entering "a wonderful new phase," with redesigned packaging, a new mint frost Cold-EEZE flavor and the planned reintroduction of a Kids-EEZE non-liquid product line (1 'The Tan Sheet' May 10, 2010, In Brief). |